Novel dihydroquinoline-based MABAs; Clues to the identity of LAS-190792: Evaluation of WO20111411802

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 2, 2012, Pages 185-192

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

2 agonist; Asthma; Bronchodilator; COPD; MABA; Muscarinic antagonist

Indexed keywords

ABEDITEROL; ABEDITEROL PLUS CORTICOSTEROID; ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIHYDROQUINOLINE DERIVATIVE; EBASTINE; EKLIRA; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INASPIR; LAS 190792; LAS 40464; MUSCARINIC RECEPTOR BLOCKING AGENT; UMECLIDINIUM; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BINDING AFFINITY; BINDING ASSAY; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INHALER; LIPOPHILICITY; NONHUMAN; PHARMACOPHORE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BRONCHODILATOR AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857527653     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.655270     Document Type: Article

References (13)

1. Chrischilles E, Gilden D, Kubisiak J, et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002;8(10):902-11
2. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115(3):635-41
3. Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin Ther Pat 2009;19(1):1-12
4. Steinfeld T, Hughes AD, Klein U, et al. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner.Mol Pharmacol 2011;79(3):389-99
5. Norman P. Dual-acting beta2 agonists/ muscarinic antagonists. Expert Opin Ther Patent 2006;16:1327-31
6. Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity. WO200602354; 2006
7. Norris V, Zhu CQ, Ambery C. The pharmacodynamics of GSK961081 in patients with COPD, [abstract V]. European Respiratory Society Annual Congress; 2011
8. Patel S, Marshall S, Summerhill S, et al. The in-vitro pharmacology of PF-3429281 - A novel inhaled dual antimuscarinic/beta2 adrenoceptor agonist [abstract P1232]. European Respiratory Society Annual Congress; 2010
9. Osborne R, Clarke N, Glossop P, et al. Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-beta2-agonist for the treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54(19):6998-7002
10. Sugiyama H, Nomura J, Hara T, et al. Pharmacological profile of a novel bronchodilator, TEI3252, as bifunctional M3 antagonist and beta2 agonist. Am J Respir Crit Care Med 2010;181:A4436.
11. Nyberg K, Ostman B, Wallerberg G. Investigations of dithienylglycolic esters. I. Preparation of methyl dithienylglycolates. Magnetically nonequivalent protons in dithienylglycolates. Acta Chem Scand 1970;24:1590-6
12. Theravance, Inc. Crystalline form of a biphenyl compound. US20060035931; 2006.
13. Astrazeneca AB, Pulmagen Therapeutics (Synergy) Ltd. Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders. WO2010067102; 2010